Literature DB >> 25246464

Drug-mediated rash: erythema multiforme versus Stevens-Johnson syndrome.

Cassandra Hidajat1, Duncan Loi1.   

Abstract

A 92-year-old woman presented with an acute onset generalised maculopapular rash with associated mucosal involvement, on a background of recent start of griseofulvin. The rash progressed rapidly over 2 days to involve most of her body, however, mucosal involvement was limited to her oral mucosa. Characteristic target lesions appeared at 72 h, and a diagnosis of erythema multiforme secondary to griseofulvin was made after further investigation and skin biopsy. The patient was monitored closely for progression of the rash and other indicators of more severe dermatological conditions such as Stevens-Johnson syndrome. She was managed symptomatically, with resolution of the rash in 4 weeks and full recovery to her premorbid level of functioning. This case details the diagnostic and management approach to erythema multiforme, a condition that warrants thorough consideration for the differential of Stevens-Johnson syndrome. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25246464      PMCID: PMC4173654          DOI: 10.1136/bcr-2014-205543

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Erythema multiforme due to griseofulvin with positive re-exposure test.

Authors:  G P Thami; S Kaur; A J Kanwar
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

2.  Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis.

Authors:  Sarah Guégan; Sylvie Bastuji-Garin; Ewa Poszepczynska-Guigné; Jean-Claude Roujeau; Jean Revuz
Journal:  J Invest Dermatol       Date:  2006-02       Impact factor: 8.551

3.  Erythema multiforme due to griseofulvin.

Authors:  M H Rustin; C B Bunker; P M Dowd; T W Robinson
Journal:  Br J Dermatol       Date:  1989-03       Impact factor: 9.302

Review 4.  Oral manifestations of erythema multiforme.

Authors:  Lilibeth Ayangco; Roy S Rogers
Journal:  Dermatol Clin       Date:  2003-01       Impact factor: 3.478

5.  Erythema multiforme and toxic epidermal necrolysis: a comparative study.

Authors:  P Paquet; G E Piérard
Journal:  Am J Dermatopathol       Date:  1997-04       Impact factor: 1.533

6.  Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.

Authors:  Ariane Auquier-Dunant; Maja Mockenhaupt; Luigi Naldi; Osvaldo Correia; Werner Schröder; Jean-Claude Roujeau
Journal:  Arch Dermatol       Date:  2002-08

7.  Erythema multiforme.

Authors:  J C Huff
Journal:  Dermatol Clin       Date:  1985-01       Impact factor: 3.478

8.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

Authors:  S Bastuji-Garin; B Rzany; R S Stern; N H Shear; L Naldi; J C Roujeau
Journal:  Arch Dermatol       Date:  1993-01

Review 9.  Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component.

Authors:  L Aurelian; F Ono; J Burnett
Journal:  Dermatol Online J       Date:  2003-02

10.  Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.

Authors:  Boni Elewski; Amir Tavakkol
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.